In order to develop a recombinant monoclonal antibody against ACTA1, CUSABIO initiated the process by immunizing a rabbit with a synthesized peptide derived from human ACTA1. Subsequently, B cells were isolated from the immunized rabbit, and RNA was extracted from these B cells. The extracted RNA was reverse-transcribed into cDNA, serving as a template for extending ACTA1 antibody genes using degenerate primers. These extended ACTA1 antibody genes were integrated into a plasmid vector and introduced into host cells for expression. The ACTA1 recombinant monoclonal antibody was then purified ...Read more